Indications for: QUILLIVANT XR
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. ≥6yrs: Individualize. Shake bottle for 10 secs before use. Initially 20mg once daily in the AM. May increase by 10–20mg per week if needed; max 60mg daily. Discontinue if no improvement seen after dose adjustment over 1 month. Switching from other methylphenidate products: discontinue and follow Quillivant XR titration schedule.
QUILLIVANT XR Contraindications:
During or within 14 days of MAOIs.
Abuse and dependence.
QUILLIVANT XR Warnings/Precautions:
Do not substitute for other methylphenidate products on a mg-per-mg basis. High potential for abuse and dependence; monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic or manic symptoms occur. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth (in children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occurs. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
QUILLIVANT XR Classification:
QUILLIVANT XR Interactions:
See Contraindications. Hypertensive crisis with MAOIs. May antagonize antihypertensive agents; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, hypertension; priapism.
Generic Drug Availability:
Bottles (w. oral dosing dispenser)—60mL, 120mL, 150mL, 180mL